Sectors

NTRA
Natera, Inc.
259.99
1 x 239.06
1 x 278.85
bid
ask
+
25.23
10.75%
01:39 PM
timesize
Ytd 13.49%
1y 51.27%
239.00
day range
261.24
133.66
52 week range
259.98
Open 241.94 Prev Close 234.76 Low 239.00 High 261.24 Mkt Cap 37.29B
Vol 1.60M Avg Vol 1.44M EPS -1.62 P/E N/A Forward P/E -1097.99
Beta 1.54 Short Ratio 2.06 Inst. Own 96.10% Dividend N/A Div Yield N/A
Ex Div Date N/A Earning 08-06 50-d Avg 209.23 200-d Avg 207.22 1yr Est 260.05
Earning
Date For Estimate Reported Surprise surprise %
2026-05-07 2026-03 0 N/A -0.03 -5.66%
2026-02-26 2025-12 0 0.35 0.81 176.09%
2025-11-06 2025-09 0 N/A -0.25 -64.10%
2025-08-07 2025-06 0 N/A -0.14 -23.33%
2025-05-08 2025-03 0 N/A 0.09 15.25%
2025-02-27 2024-12 0 N/A 0.01 2.38%
Upgrade / Downgrade
Date Firm Action From To
2026-06-05 Goldman Sachs Upgrade Buy Neutral
2026-05-11 BTIG Upgrade Buy Buy
2026-05-08 JP Morgan Upgrade Overweight Overweight
2026-05-08 Evercore ISI Group Upgrade Outperform Outperform
2026-05-08 Wells Fargo Upgrade Equal-Weight Equal-Weight
2026-04-14 William Blair Upgrade Outperform
Profile
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.
Insider Holder
Date Name Relation Quantity Description
2026-05-31 BOTHA ROELOF FREDERICK Director 0.00 Sale
2026-05-03 BROPHY MICHAEL BURKES Chief Financial Officer 57.50K Sale
2026-06-03 CHAPMAN STEVEN LEONARD Chief Executive Officer 108.74K Sale
2026-05-25 FESKO JOHN President 185.78K Sale
2025-04-24 HEALY JAMES I Director 1.60M Stock Award(Grant)
2026-05-31 MOSHKEVICH SOLOMON Officer 137.64K Sale
Institution Ownership
Report Date Organization Position Value Percentage
2026-03-30 JPMORGAN CHASE & CO 13.39M 3.14B 9.35%
2026-03-30 Price (T.Rowe) Associates Inc 12.18M 2.86B 8.51%
2026-03-30 Blackrock Inc. 10.68M 2.51B 7.46%
2026-03-30 Vanguard Capital Management LLC 6.01M 1.41B 4.20%
2026-03-30 Vanguard Portfolio Management LLC 5.64M 1.33B 3.94%
2026-03-30 Wellington Management Group, LLP 4.77M 1.12B 3.33%
Fund Ownership
Report Date Organization Position Value Percentage
2026-03-30 JPMorgan Trust II-JPMorgan Large Cap Growth Fund 6.03M 1.42B 4.21%
2026-03-30 VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund 4.21M 988.44M 2.94%
2026-03-30 VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund 3.05M 717.10M 2.13%
2026-03-30 VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund 1.71M 401.24M 1.19%
2026-03-30 VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund 1.54M 362.47M 1.08%
2026-03-30 Franklin Custodian Funds-FRANKLIN DYNATECH FUND 1.45M 340.40M 1.01%